Scavenging intestinal ROS with black phosphorus nanosheets ameliorated rheumatoid arthritis by reshaping gut microbiota to elevate kynurenic acid, which activated the AhR pathway to promote Treg differentiation and restore Treg/Th17 balance.
Key Findings
Results
Oral administration of black phosphorus nanosheets (BPNSs) significantly ameliorated disease severity in collagen-induced arthritis (CIA) mice by eliminating intestinal excess reactive oxygen species.
BPNSs were used as ROS scavengers administered via oral route in the CIA mouse model of rheumatoid arthritis.
BPNS treatment reduced arthritis progression and disease severity as measured by standard CIA scoring metrics.
The therapeutic effect was attributed to the ability of BPNSs to scavenge excess ROS within the intestinal environment.
BPNSs were described as 'effective ROS scavengers' that could selectively modulate the gut ecosystem.
Results
BPNSs selectively reshaped the gut microbiota composition and altered its metabolic profile, specifically elevating the relative abundance of the tryptophan-derived metabolite kynurenic acid (KYNA).
BPNS treatment led to selective changes in gut microbial community composition in CIA mice.
Metabolic profiling revealed altered metabolite profiles following BPNS administration.
Kynurenic acid (KYNA), a tryptophan-derived microbial metabolite, was specifically elevated in relative abundance following BPNS treatment.
The connection between intestinal ROS scavenging and KYNA elevation suggests a gut microbiota-mediated mechanism linking ROS levels to tryptophan metabolism.
Results
Elevated KYNA activated the aryl hydrocarbon receptor (AhR) pathway in naïve CD4+ T cells, promoting their differentiation into Treg cells through inhibition of the AKT/mTOR signaling pathway.
KYNA acted mechanistically on naïve CD4+ T cells via AhR pathway activation.
AhR pathway activation by KYNA resulted in promotion of regulatory T cell (Treg) differentiation.
The pro-Treg effect of KYNA was mediated through inhibition of the AKT/mTOR signaling pathway.
This represents a mechanistic link between a gut microbial metabolite and peripheral immune cell differentiation.
Results
Direct administration of KYNA in CIA mice maintained Treg/Th17 balance, attenuated arthritis progression, and enhanced intestinal barrier integrity.
KYNA treatment was tested independently in CIA mice to corroborate the mechanistic findings from BPNS experiments.
KYNA administration restored the balance between regulatory T cells (Treg) and pro-inflammatory Th17 cells.
Arthritis progression was attenuated following KYNA treatment in CIA mice.
KYNA treatment also enhanced intestinal barrier integrity, suggesting a dual role in gut homeostasis and systemic immune modulation.
These findings confirmed the therapeutic relevance of KYNA as a key mediator in the BPNS-mediated treatment pathway.
Discussion
The study elucidates a novel gut-immune-bone axis wherein scavenging intestinal ROS drives KYNA-mediated AhR-dependent Treg cell differentiation.
The proposed axis connects intestinal ROS levels → gut microbiota composition → KYNA production → AhR activation → Treg differentiation → Treg/Th17 balance → arthritis outcomes.
Excessive ROS were identified as 'critical drivers of microecological immunity disturbance, contributing directly to the inflammatory cascade.'
The gut-immune-bone axis described represents a mechanistic framework linking intestinal oxidative stress to systemic autoimmune joint disease.
The findings propose 'a promising ROS scavenging-based strategy for RA treatment' based on this axis.
Background
Rheumatoid arthritis progression in CIA mice is closely associated with impaired gut microbiota homeostasis and excessive intestinal reactive oxygen species.
The study positioned gut microbiota dysbiosis as a key feature of RA-associated immune dysregulation.
Excessive ROS in the intestinal environment were linked to disruption of microecological immune balance.
The CIA mouse model was used to recapitulate these gut-immune interactions observed in RA.
This background contextualizes intestinal ROS as an upstream driver rather than a downstream consequence of RA-associated inflammation.
What This Means
This research suggests that the gut plays a previously underappreciated role in rheumatoid arthritis (RA), a chronic autoimmune disease that causes painful joint inflammation. The study found that excessive levels of reactive oxygen species (ROS) — chemically reactive molecules that can damage cells — in the intestines disrupt the balance of gut bacteria and contribute to the immune system dysfunction seen in RA. By using tiny particles called black phosphorus nanosheets (BPNSs) to neutralize this intestinal oxidative stress in mice with arthritis, the researchers were able to significantly reduce disease severity.
The mechanism works through a chain of events: when intestinal ROS are reduced by BPNSs, the gut microbiota composition changes favorably, leading to increased production of a molecule called kynurenic acid (KYNA), which is derived from the amino acid tryptophan. KYNA then activates a molecular sensor called the aryl hydrocarbon receptor (AhR) in immune cells, which steers immune cells toward a regulatory, anti-inflammatory type (called Treg cells) rather than the pro-inflammatory type (called Th17 cells) that drives RA. When KYNA was given directly to arthritic mice, it also restored this immune balance, reduced arthritis progression, and strengthened the gut lining.
This research suggests a new 'gut-immune-bone axis' connecting intestinal oxidative stress to systemic autoimmune joint disease, and points to both intestinal ROS scavenging and KYNA supplementation as potential therapeutic strategies for RA. The findings highlight how the health of the gut microbiome and its metabolic outputs may have far-reaching effects on immune regulation beyond the gut itself.